tirzepatide latest news https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Lilly's new drug Mounjaro (tirzepatide

doi: 10.1016/s1096-6374(02)00044-8

The body has finite capacity to process metabolic interventions simultaneously

Compounded versions of both are substantially cheaper, typically $200-400 per month depending on pharmacy and dose

Exercise helps support strength, muscle, mobility, energy, confidence, mood, heart health and long-term lifestyle change

Jones B, McGlone ER, Fang Z, Pickford P, Corra IR, Jr., Oishi A, Jockers R, Inoue A, Kumar S, Grlitz F, et al: Genetic and biased agonist-mediated reductions in -arrestin recruitment prolong cAMP signaling at glucagon family receptors

Studies show semaglutide might lead to more hair loss